{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-049604","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.765832+00:00","generated_at":"2026-05-17T00:24:17.847893+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Context Therapeutics Q3 net loss $9.7M; early clinical data for CTIM-76 and CT-95","bullets":["Q3 net loss $9.7M, down from $17.5M YoY; cash $76.9M sufficient into 2027.","CTIM-76 Phase 1: 12 patients; RECIST response observed from Cohort 3; no CRS>Grade1, no DLT.","CT-95 Phase 1: 6 patients; approaching target dose with Cohort 4; no CRS>Grade2.","CT-202 (Nectin-4 x CD3) preclinical; expects regulatory filing for first-in-human trial in Q2 2026.","Anticipates updated CTIM-76 Phase 1a data and Phase 1b dose selection in Q2 2026; CT-95 data mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-049604","json":"https://secwatch.observer/filing/0001628280-25-049604.json","markdown":"https://secwatch.observer/filing/0001628280-25-049604.md","text":"https://secwatch.observer/filing/0001628280-25-049604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000162828025049604/0001628280-25-049604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000162828025049604/cntx-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:24:17.847893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}